XKH002
/ Kanova Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 10, 2024
Phase I of XKH002 Injection in Patients
(clinicaltrials.gov)
- P1 | N=110 | Recruiting | Sponsor: Zhejiang Kanova Biopharmaceutical Co., LTD | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
January 09, 2024
Phase I of XKH002 Injection in Patients
(clinicaltrials.gov)
- P1 | N=110 | Not yet recruiting | Sponsor: Suzhou Kanova Biopharmaceutical Co., LTD
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1